Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

02 May 2003

Pre-clinical development of PARP-1 inhibitors for cancer therapy

N. Curtin, M. Batey, T. Boritzki, C. Calabrese, S. Canan-Koch, R. Griffin, Z. Hostomsky, S. Kyle, D. Newell, I. Stratford, L. Wang, S. Webber, K. Williams

Med Sci Monit 2003; 9(1): 18-0 :: ID: 15065

Abstract

Both inhibitor and molecular genetic studies demonstrate that impeding PARP-1-mediated DNA repair enhances the cytotoxicity of DNA-damaging cancer therapies. However, the therapeutic potential of this approach has not been investigated previously due to the poor potency, solubility and limited specificity of classical inhibitors. Development of these early benzamide PARP inhibitors (Ki 10 KM) led to the discovery of the more potent inhibitors NU1025 and NU1085. Subsequently, structure-based drug design led to the identification of a very potent, water-soluble PARP-1 inhibitor, AG14361. AG14361 (Ki75% for 4 hours. Non-toxic doses of AG14361 markedly enhanced the antitumour activity of temozolomide, irinotecan and ionising radiation on human tumour xenografts, and AG14361-temozolomide combinations caused complete regression of SW620 xenografts.AG14361 has the required pharmacological properties (potency, specificity, stability and in vivo activity) to address the therapeutic potential of PARP-1 inhibition for the treatment of human cancer.

Keywords: PARP-1 inhibitors, chemotherapy and radiotherapy of cancer, in vitro and in vivo efficacy

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750